.ANALYSIS FEATURE.06 August 2024.
A huge randomized measured trial along with cisgender females highlights the obstacles of adherence to a day-to-day oral preexposure prophylaxis program and also displays that twice-yearly injection of lenacapavir can preserve helpful HIV deterrence amounts over 6 months.